- Home
- MRKR vs TENX Comparison
MRKR vs TENX Comparison
Compare MRKR & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- TENX
- Stock Information
- Founded
- MRKR N/A
- TENX 1967
- Country
- MRKR United States
- TENX United States
- Employees
- MRKR N/A
- TENX 5
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- TENX Health Care
- Exchange
- MRKR Nasdaq
- TENX Nasdaq
- Market Cap
- MRKR 16.1M
- TENX 21.7M
- IPO Year
- MRKR N/A
- TENX N/A
- Fundamental
- Price
- MRKR $1.18
- TENX $6.36
- Analyst Decision
- MRKR Strong Buy
- TENX Strong Buy
- Analyst Count
- MRKR 2
- TENX 3
- Target Price
- MRKR $13.50
- TENX $16.00
- AVG Volume (30 Days)
- MRKR 239.7K
- TENX 44.0K
- Earning Date
- MRKR 03-25-2025
- TENX 03-27-2025
- Dividend Yield
- MRKR N/A
- TENX N/A
- EPS Growth
- MRKR N/A
- TENX N/A
- EPS
- MRKR N/A
- TENX N/A
- Revenue
- MRKR $5,395,849.00
- TENX N/A
- Revenue This Year
- MRKR $195.40
- TENX N/A
- Revenue Next Year
- MRKR N/A
- TENX N/A
- P/E Ratio
- MRKR N/A
- TENX N/A
- Revenue Growth
- MRKR 79.04
- TENX N/A
- 52 Week Low
- MRKR $1.13
- TENX $2.77
- 52 Week High
- MRKR $5.99
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- MRKR 33.38
- TENX 50.89
- Support Level
- MRKR $1.35
- TENX $5.80
- Resistance Level
- MRKR $1.99
- TENX $6.59
- Average True Range (ATR)
- MRKR 0.22
- TENX 0.42
- MACD
- MRKR 0.01
- TENX 0.01
- Stochastic Oscillator
- MRKR 5.21
- TENX 66.67
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.